JP2022036976A5 - - Google Patents

Download PDF

Info

Publication number
JP2022036976A5
JP2022036976A5 JP2021188305A JP2021188305A JP2022036976A5 JP 2022036976 A5 JP2022036976 A5 JP 2022036976A5 JP 2021188305 A JP2021188305 A JP 2021188305A JP 2021188305 A JP2021188305 A JP 2021188305A JP 2022036976 A5 JP2022036976 A5 JP 2022036976A5
Authority
JP
Japan
Prior art keywords
antigen
car
binding domain
domain
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021188305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022036976A (ja
Filing date
Publication date
Priority claimed from JP2017525517A external-priority patent/JP7023708B2/ja
Application filed filed Critical
Publication of JP2022036976A publication Critical patent/JP2022036976A/ja
Publication of JP2022036976A5 publication Critical patent/JP2022036976A5/ja
Pending legal-status Critical Current

Links

JP2021188305A 2014-11-12 2021-11-19 阻害性キメラ抗原受容体 Pending JP2022036976A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462078927P 2014-11-12 2014-11-12
US62/078,927 2014-11-12
US201462081960P 2014-11-19 2014-11-19
US62/081,960 2014-11-19
JP2017525517A JP7023708B2 (ja) 2014-11-12 2015-11-09 阻害性キメラ抗原受容体
PCT/IB2015/058650 WO2016075612A1 (en) 2014-11-12 2015-11-09 Inhibitory chimeric antigen receptors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017525517A Division JP7023708B2 (ja) 2014-11-12 2015-11-09 阻害性キメラ抗原受容体

Publications (2)

Publication Number Publication Date
JP2022036976A JP2022036976A (ja) 2022-03-08
JP2022036976A5 true JP2022036976A5 (https=) 2022-06-28

Family

ID=54695797

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017525517A Active JP7023708B2 (ja) 2014-11-12 2015-11-09 阻害性キメラ抗原受容体
JP2021188305A Pending JP2022036976A (ja) 2014-11-12 2021-11-19 阻害性キメラ抗原受容体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017525517A Active JP7023708B2 (ja) 2014-11-12 2015-11-09 阻害性キメラ抗原受容体

Country Status (6)

Country Link
US (3) US11072644B2 (https=)
EP (1) EP3218394A1 (https=)
JP (2) JP7023708B2 (https=)
AU (1) AU2015344769B2 (https=)
CA (1) CA2967222C (https=)
WO (1) WO2016075612A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072526A1 (en) * 2012-11-12 2014-05-15 Ruprecht-Karls-Universität Heidelberg Development of hbv- and/or hdv-susceptible cells, cell lines and non-human animals
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
CN109219445B (zh) 2016-04-01 2022-08-26 上海煦顼技术有限公司 嵌合抗原受体修饰细胞治疗癌症的应用
AU2017271606B2 (en) * 2016-05-27 2024-08-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services FLT3-specific chimeric antigen receptors and methods using same
MX2019003462A (es) * 2016-09-28 2019-08-16 Gavish Galilee Bio Appl Ltd Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
WO2018064921A1 (en) * 2016-10-06 2018-04-12 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
WO2018104473A1 (en) * 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
JP7317718B2 (ja) 2017-06-02 2023-07-31 ファイザー・インク Flt3を標的にするキメラ抗原受容体
KR20200071740A (ko) 2017-09-28 2020-06-19 임팩트-바이오 리미티드. 저해성 키메라 항원 수용체 (icar)를 제조하기 위한 보편적 플랫폼
US20190338244A1 (en) * 2017-11-30 2019-11-07 New York Medical College Multipotent adult stem cells: characterization and use
SG11202006050XA (en) * 2017-12-29 2020-07-29 Memorial Sloan Kettering Cancer Center Enhanced chimeric antigen receptors and uses thereof
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
US20200316120A1 (en) * 2018-09-28 2020-10-08 Immpact-Bio Ltd. METHODS FOR IDENTIFYING ACTIVATING ANTIGEN RECEPTOR (aCAR)/INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR) PAIRS FOR USE IN CANCER THERAPIES
CN113164576A (zh) 2018-10-05 2021-07-23 圣安娜儿童癌症研究中心 嵌合抗原受体(car)组
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
WO2020168122A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
JP7739261B2 (ja) * 2019-08-09 2025-09-16 エイ2・バイオセラピューティクス・インコーポレイテッド ヘテロ接合性の喪失に応答する細胞表面受容体
JP2022546315A (ja) * 2019-08-20 2022-11-04 センティ バイオサイエンシズ インコーポレイテッド キメラ抑制性受容体
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
WO2021068068A1 (en) * 2019-10-08 2021-04-15 Provincial Health Services Authority Chimeric cytokine receptors
WO2021096868A1 (en) 2019-11-12 2021-05-20 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
EP4073103A1 (en) 2019-12-11 2022-10-19 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
CN115298209A (zh) * 2020-02-20 2022-11-04 森迪生物科学公司 抑制性嵌合受体构造体
CN115397845A (zh) * 2020-02-20 2022-11-25 森迪生物科学公司 抑制性嵌合受体架构
GB202004832D0 (en) * 2020-04-01 2020-05-13 Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa Therapeutic agaents, pharmaceutical compositions, and associated biomarkers
AU2021328478A1 (en) 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
KR102859550B1 (ko) 2020-08-20 2025-09-16 에이투 바이오쎄라퓨틱스, 인크. Ceacam 양성 암을 치료하기 위한 조성물 및 방법
US20220090015A1 (en) * 2020-09-21 2022-03-24 A2 Biotherapeutics, Inc. Engineered immune cells with multiplex and localized activity
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
AU2022245215A1 (en) * 2021-03-22 2023-10-12 Memorial Hospital For Cancer And Allied Diseases Cd38 chimeric co-stimulating receptor and uses thereof
WO2022204326A1 (en) * 2021-03-24 2022-09-29 The Regents Of The University Of California Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
WO2022251377A1 (en) * 2021-05-26 2022-12-01 Board Of Regents, The University Of Texas System Inhibitory chimeric antigen receptor prevents on-target off-tumor effects of adoptive cell therapy
CN115028682B (zh) * 2022-06-30 2025-06-06 合肥工业大学 一种来源于干腌火腿的增咸肽及制备方法
KR20250158048A (ko) 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템
CN119506295B (zh) * 2025-01-21 2025-05-30 上海皓鸿生物医药科技有限公司 一种前列腺特异性膜抗原的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
PH12016502073B1 (en) * 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9307495B2 (en) 2011-09-12 2016-04-05 Apple Inc. Monitoring a battery in a portable electronic device
EP2970426B1 (en) * 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2015142314A1 (en) * 2013-03-15 2015-09-24 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
AU2014248119B2 (en) 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-bcma嵌合抗原受體治療癌症
CA2969384A1 (en) 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
WO2016138034A1 (en) * 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
MX2019003462A (es) * 2016-09-28 2019-08-16 Gavish Galilee Bio Appl Ltd Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
EP3703709A4 (en) * 2017-10-31 2021-09-01 The General Hospital Corporation MOLECULAR PERMUTATION MEDIATION CONTROL OF MANIPULATED CELLS
WO2021173442A1 (en) * 2020-02-24 2021-09-02 The Regents Of The University Of California In-series synthetic receptor and-gate circuits for expression of a therapeutic payload by engineered cells

Similar Documents

Publication Publication Date Title
JP2022036976A5 (https=)
Chen et al. Bispecific antibodies in cancer immunotherapy
Zhang et al. Natural killer cell engagers (NKCEs): a new frontier in cancer immunotherapy
Li et al. A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer
US20240342283A1 (en) ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors
JP2021525524A5 (https=)
HRP20250135T1 (hr) Notch receptori sa zglobnom domenom
JP2021536265A5 (https=)
JP2019537433A5 (https=)
JPWO2019157533A5 (https=)
JP2019532625A5 (https=)
US20160090426A1 (en) Construction and application of bispecific antibody EpCAMxCD3
JP2021520788A5 (https=)
GB2607452A (en) Anti-TCR antibody molecules and uses thereof
JP2013519379A5 (https=)
CN104592392B (zh) 一种双特异性抗体EpCAM×CD3的构建及应用
HRP20220767T1 (hr) Liječenje raka uporabom humaniziranog kimernog receptora antigena anti-cd19
JP2021514631A5 (https=)
JP2021501587A5 (https=)
JP2022524906A (ja) 細胞免疫療法の組み合わせ
Peng et al. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA
Stamova et al. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses
JPWO2020010110A5 (https=)
JP2020501512A5 (https=)
JPWO2020051493A5 (https=)